IP Library Granted Patent US 8,877,159
Granted Patent B2
US 8,877,159 · App. 13/964,315 · Granted Nov 4, 2014

Phospholipid analogs as diapeutic agents and methods thereof

Inventors: Jamey P. Weichert (Fitchburg, WI); Marc Longino (Verona, WI); Anatoly Pinchuk (Madison, WI)
Assignee: Cellectar, Inc.
A61K51/0408A61K51/04C12Q1/34G01N33/57492A61K49/0017C07F13/005
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,877,159
App. No.
13/964,315
Granted
Nov 4, 2014
Kind
B2
Abstract

The present invention provides methods and uses of phospholipid ether analogs as diagnostic and therapeutic agents for numerous cancers.

Claims (16)

1. A method for the treatment of a cancer in a subject comprising:

administering, to the subject, an effective amount of 18-(p-iodophenyl)octadecyl phosphocholine for treating the cancer, wherein the iodo moiety of the 18-(p-iodophenyl)octadecyl phosphocholine is 125 I or 131 I, and wherein the cancer is intestinal cancer, adrenal cancer, liver cancer, subcutaneous cancer, retinoblastoma, cervical cancer, brain cancer, bladder cancer, or leukemia.

2. The method of claim 1 , wherein the iodo moiety is 125 I.

3. The method of claim 1 , wherein the iodo moiety is 131 I.

4. The method of claim 1 , comprising administering 5-20 μCi/200 g of body weight of the 18-(p-iodophenyl)octadecyl phosphocholine to the subject.

5. The method of claim 1 , comprising administering 15-20 μCi/200 g of body weight of the 18-(p-iodophenyl)octadecyl phosphocholine to the subject.

6. The method of claim 1 , wherein the subject is human.

7. The method of claim 1 , wherein the cancer is intestinal cancer.

8. The method of claim 1 , wherein the cancer is adrenal cancer.

9. The method of claim 1 , wherein the cancer is liver cancer.

10. The method of claim 1 , wherein the cancer is subcutaneous cancer.

11. The method of claim 1 , wherein the cancer is retinoblastoma.

12. The method of claim 1 , wherein the cancer is cervical cancer.

13. The method of claim 1 , wherein the cancer is brain cancer.

14. The method of claim 1 , wherein the cancer is bladder cancer.

15. The method of claim 1 , wherein the cancer is leukemia.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 10, 2013
From: WEICHERT, JAMEY; LONGINO, MARC; PINCHUK, ANATOLY
To: CELLECTAR, LLC
Reel/Frame 031174/0796 →
MERGER Recorded Sep 10, 2013
From: CELLECTAR, INC.
To: CELL ACQUISITION CORP.
Reel/Frame 031175/0481 →
CHANGE OF NAME Recorded Sep 10, 2013
From: CELL ACQUISITION CORP.
To: CELLECTAR, INC.
Reel/Frame 031200/0419 →
CONVERSION Recorded Sep 10, 2013
From: CELLECTAR, LLC
To: CELLECTAR, INC.
Reel/Frame 031200/0687 →
Continuity (3)
Continuation 10906687 · Mar 2, 2005
Provisional Application 60521166 · Mar 2, 2004
Related Publication 20140023587A1 · Jan 23, 2014